Clinical Trial Researchers Routinely Violating Federal Laws

Rarely do the findings of a single journal study affect everyone. This is an exception.

Monique L. Anderson, MD of Duke University and colleagues are reporting in the New England Journal of Medicine that the overwhelming majority of clinical trials that take place at least partly in the United States fail to post their results to ClinicalTrials.gov, the federal registry, within one year of completion, despite the fact that failing to do so is against the law.

Research looked at clinical trials on all subjects over five year span

The researchers looked at over 13,000 completed or terminated trials in the registry between 2008 and 2013 which were subject to the reporting requirement.

They found result summaries for just 13.4 percent of them.

"Industry, the NIH, and other government and academic institutions all performed poorly with respect to ethical obligations for transparency," they wrote.

Trials funded by industry (by, for example, a pharmaceutical company) were most likely to report their results on time, followed by trials funded by the National Institutes of Health (NIH). Trials funded by non-NIH government agencies or academic institutions were worse than either the first two.

But collectively, they were only reporting on time 13.4 percent of the time. And five years down the road, they all performed equally poorly.

Kathy Hudson, PhD, NIH Deputy Director of Science Outreach and Policy, told MedPage Today in an email that the findings were unacceptable. "The study confirms the need for the NIH’s newly proposed policy that requires all NIH-funded investigators to submit clinical trial results information or risk losing their funding.”

The FDA Amendment Act of 2007 requires the sponsors of certain clinical trials to register and report basic results on ClinicalTrials.gov. This applies to medical devices, to biologics, and to all non-phase I trials testing drugs.

Some legal exemptions notwithstanding, these trials are required to report prespecified primary outcome data within a year of the final data collection or termination of the trial. Penalties for failing this basic demand include:

    Issuance of a "failure to submit" notification on ClinicalTrials.gov
  • Civil fines up to $10,000 per day
  • loss of NIH funding

However, since some of the wording of the law is still under debate, not a single clinical trial sponsor has been hit with a penalty yet.

Doctors routinely recommend that patients join a clinical trial. This recommendation can be found all over the National Comprehensive Cancer Network's clinical practice guidelines.

Yet, this study, coupled with the work being done by Dr. Ben Goldacre and others in revealing just how often industry has chosen to bury trial data that they don't like (the campaign), and the recent revelation that many clinical trial researchers are not including their FDA violations along with their published reports, hardly amount to a ringing endorsement of the US clinical trial system.

Source: MedPage Today

More Articles

More Articles

This article looks at the Non-Hodgkin's Lymphoma survival rate as well as the Non-Hodgkin's Lymphoma mortality rate ....

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...